Ozempic reveals brain's 'craving center' in lateral septum
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Ozempic and related GLP-1 agonists (including Wegovy) appear to curb more than hunger: human studies show reduced alcohol consumption, and preclinical work shows reductions in cocaine, amphetamine, opiate, and nicotine use
- The lateral septum, a brain region packed with GLP-1 receptors, is now emerging as the likely 'craving center' — linking episodic memories from the hippocampus with the dopamine-based reward machinery
- The classical dopamine reward regions — the ventral tegmental area (VTA) and nucleus accumbens — lack significant GLP-1 receptor density, ruling them out as the direct site of the anti-consumption effect
- GLP-1 activation directly in the lateral septum has recently been shown to reduce food consumption in mice, and a separate 2026 study demonstrated the same effect for alcohol consumption
- Robert Munn's lab at the University of Otago has shown this year that GLP-1 drugs reduce activity in the lateral septum that may impair its communication with other brain regions
- The discovery could open new treatment approaches for obesity, alcohol dependence, and other substance use disorders, according to the source
Why it matters: The mainstream Ozempic story is about weight loss, but this research reframes GLP-1 agonists as tools for mapping — and potentially treating — addiction itself. Pinning the anti-craving effect to the lateral septum gives pharmaceutical researchers a concrete anatomical target after decades of failed attempts to disrupt addiction through the classical dopamine reward circuitry.
Ask SkimNews
